Form S-3ASR Agios Pharm For: 13 February
- Investing.com
- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Agios Pharm (AGIO)
Agios Pharm stock price live, this page displays NASDAQ AGIO stock exchange data. View the AGIO premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Agios Pharm real time stock price chart below.
What Is the Agios Pharm Stock Price Today?
The Agios Pharm stock price today is 27.96.
What Is the Stock Symbol for Agios Pharm?
The stock symbol for Agios Pharm is "AGIO."
What Stock Exchange Does Agios Pharm Trade On?
Agios Pharm is listed and trades on the NASDAQ stock exchange.
Is Agios Pharm a Good Stock to Buy?
Determining whether Agios Pharm—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the AGIO quote. (ISIN: US00847X1046)
What Is the Agios Pharm Stock Price Today?
The Agios Pharm stock price today is 27.96.
What Is the Stock Symbol for Agios Pharm?
The stock symbol for Agios Pharm is "AGIO."
What Stock Exchange Does Agios Pharm Trade On?
Agios Pharm is listed and trades on the NASDAQ stock exchange.
Is Agios Pharm a Good Stock to Buy?
Determining whether Agios Pharm—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the AGIO quote. (ISIN: US00847X1046)
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
27.76
28.97
52 wk Range
22.24
46.00
AGIO is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
27.7628.97
52 wk Range
22.2446.00
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
AGIO Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PricePrice Target
38.13
Upside
+36.36%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
2 analysts have revised their earnings upwards for the upcoming period
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Sell
Moving Averages
Buy
Agios Pharm Company Profile
Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency. The company’s PYRUKYND product is also used for the treatment of sickle cell disease that is in phase 3 clinical trial; for the treatment of PK deficiency in pediatric patients; and AQVESME for the treatment of adult patients with non-transfusion dependent and transfusion-dependent alpha- or beta-thalassemia. In addition, it developed tebapivat, a PK activator for the treatment of lower-risk myelodysplastic syndrome and sickle cell disease; AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria (PKU); and AG-236, an siRNA in-licensed from Alnylam, targeting the transmembrane serine protease 6 (TMPRSS6) gene for the treatment of polycythemia vera. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Agios Pharm SWOT Analysis
Pyrukynd's Promise | Explore Agios's lead drug candidate Pyrukynd, potentially the next treatment for thalassemia and sickle cell disease, awaiting FDA decision by September 2025 |
Financial Fortitude | With $1.4 billion in cash and a robust financial health score, Agios stands well-positioned to fund its ambitious drug development pipeline |
Market Dynamics | Delve into Agios's competitive landscape, including challenges from Novo Nordisk's etavopivat and emerging liver safety signals for Pyrukynd |
Analyst Outlook | Analyst price targets range from $38 to $71, with an average of $56.25, suggesting potential upside from the current $30.11 trading price |
Agios Pharm Earnings Call Summary for Q4/2025
- Agios reported 86% YoY increase in Q4 2025 PYRUKYND revenue to $20M, with full-year revenue reaching $54M and stock rising 1.12% to $28.02 premarket.
- Company maintains strong cash position of approximately $1.2 billion while projecting U.S. PK deficiency revenues between $45-50 million for 2026.
- FDA approval of ACTIVASE for thalassemia treatment marks significant milestone with 44 prescriptions reported in first five weeks of launch.
- CEO Brian Goff highlighted expansion opportunities for PK activation franchise, noting 'combined global market potential across current pipeline indications exceeds $10 billion.'
- Agios is preparing for potential European market entry for sickle cell disease treatments while exploring multiple regulatory pathways to expedite market access.
Last Updated: 02/12/2026, 10:12 PM
Read Full TranscriptCompare AGIO to Peers and Sector
Metrics to compare | AGIO | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipAGIOPeersSector | |
|---|---|---|---|---|
P/E Ratio | −4.0x | −2.1x | −0.5x | |
PEG Ratio | 0.02 | 0.05 | 0.00 | |
Price/Book | 1.4x | 2.2x | 2.6x | |
Price / LTM Sales | 30.3x | 9.0x | 3.3x | |
Upside (Analyst Target) | 30.5% | 254.5% | 47.1% | |
Fair Value Upside | Unlock | 15.8% | 5.8% | Unlock |
Analyst Ratings
7 Buy
3 Hold
0 Sell
Ratings:
10 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 38.13
(+36.36% Upside)
Earnings
Latest Release
Feb 12, 2026
EPS / Forecast
-1.86 / -1.95
Revenue / Forecast
19.97M / 12.06M
People Also Watch
FAQ
What Is the Agios Pharm (AGIO) Stock Price Today?
The Agios Pharm stock price today is 27.96
What Stock Exchange Does Agios Pharm Trade On?
Agios Pharm is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Agios Pharm?
The stock symbol for Agios Pharm is "AGIO."
What Is the Agios Pharm Market Cap?
As of today, Agios Pharm market cap is 1.64B.
What Is Agios Pharm's Earnings Per Share (TTM)?
The Agios Pharm EPS (TTM) is -7.12.
When Is the Next Agios Pharm Earnings Date?
Agios Pharm will release its next earnings report on Apr 30, 2026.
From a Technical Analysis Perspective, Is AGIO a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Buy.
How Many Times Has Agios Pharm Stock Split?
Agios Pharm has split 0 times.
How Many Employees Does Agios Pharm Have?
Agios Pharm has 487 employees.
What is the current trading status of Agios Pharm (AGIO)?
As of Feb 14, 2026, Agios Pharm (AGIO) is trading at a price of 27.96, with a previous close of 28.07. The stock has fluctuated within a day range of 27.76 to 28.97, while its 52-week range spans from 22.24 to 46.00.
What Is Agios Pharm (AGIO) Price Target According to Analysts?
The average 12-month price target for Agios Pharm is USD38.13, with a high estimate of USD65 and a low estimate of USD25. 7 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +36.36% Upside potential.
What Is the AGIO Premarket Price?
AGIO's last pre-market stock price is 28.72. The pre-market share volume is 177.00, and the stock has decreased by 0.65, or 2.32%.
What Is the AGIO After Hours Price?
AGIO's last after hours stock price is 27.99, the stock has decreased by 0.03, or 0.11%.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.